Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$22.81 +0.0%	$21.56	$15.47 ▼ $36.37	$780.05M	1.26	217,295 shs	284,039 shs
CGON CG Oncology	$26.07 +0.0%	$25.32	$14.80 ▼ $40.47	$1.99B	0.86	837,857 shs	694,133 shs
JNJ Johnson & Johnson	$152.25 0.0%	$153.85	$140.68 ▼ $169.99	$366.40B	0.42	7.98 million shs	7.15 million shs
UPB Upstream Bio	$10.94 +0.5%	$9.76	$5.14 ▼ $29.46	$585.81M	N/A	339,572 shs	271,543 shs
UPB Upstream Bio	$10.94 +0.5%	$9.76	$5.14 ▼ $29.46	$585.81M	N/A	339,572 shs	271,543 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	+0.04%	-8.36%	+10.57%	+20.37%	+34.57%
CGON CG Oncology	+0.04%	-0.80%	+2.16%	-1.32%	-14.58%
JNJ Johnson & Johnson	-0.05%	+0.98%	-0.65%	-6.95%	+3.71%
UPB Upstream Bio	+0.46%	+2.82%	+13.72%	+59.24%	+1,093,999,900.00%
UPB Upstream Bio	+0.46%	+2.82%	+13.72%	+59.24%	+1,093,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.2443 of 5 stars	3.6	0.0	0.0	0.0	2.1	0.8	0.0
CGON CG Oncology	2.1428 of 5 stars	4.5	1.0	0.0	0.0	1.7	0.8	0.0
JNJ Johnson & Johnson	4.9484 of 5 stars	3.3	5.0	4.2	3.9	3.0	1.7	1.9
UPB Upstream Bio	1.7611 of 5 stars	3.5	0.0	0.0	0.0	1.6	0.8	0.6
UPB Upstream Bio	1.7611 of 5 stars	3.5	0.0	0.0	0.0	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$40.00	75.36% Upside
CGON CG Oncology	3.00	Buy	$58.67	125.04% Upside
JNJ Johnson & Johnson	2.55	Moderate Buy	$170.88	12.24% Upside
UPB Upstream Bio	3.00	Buy	$56.50	416.45% Upside
UPB Upstream Bio	3.00	Buy	$56.50	416.45% Upside

Current Analyst Ratings Breakdown

Latest UPB, CGON, AVBP, JNJ, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	JNJ Johnson & Johnson	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$169.00 ➝ $153.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
4/29/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
CGON CG Oncology	$1.14M	1,743.03	N/A	N/A	$9.63 per share	2.71
JNJ Johnson & Johnson	$88.82B	4.12	$13.11 per share	11.61	$29.69 per share	5.13
UPB Upstream Bio	$2.37M	248.30	N/A	N/A	$8.77 per share	1.25
UPB Upstream Bio	$2.37M	248.30	N/A	N/A	$8.77 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
CGON CG Oncology	-$88.04M	-$1.51	N/A	N/A	N/A	-15,945.17%	-16.71%	-16.24%	8/14/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$8.99	16.94	13.75	2.31	24.42%	33.46%	13.30%	7/16/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest UPB, CGON, AVBP, JNJ, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	3.42%	N/A	57.84%	64 Years
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Latest UPB, CGON, AVBP, JNJ, and UPB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
CGON CG Oncology	N/A	30.97	30.97
JNJ Johnson & Johnson	0.49	1.26	1.03
UPB Upstream Bio	N/A	47.43	47.43
UPB Upstream Bio	N/A	47.43	47.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
CGON CG Oncology	26.56%
JNJ Johnson & Johnson	69.55%
UPB Upstream Bio	N/A
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
CGON CG Oncology	7.40%
JNJ Johnson & Johnson	0.16%
UPB Upstream Bio	13.56%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
CGON CG Oncology	61	76.22 million	70.58 million	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
UPB Upstream Bio	38	53.79 million	46.50 million	N/A
UPB Upstream Bio	38	53.79 million	46.50 million	N/A

UPB, CGON, AVBP, JNJ, and UPB Headlines

Recent News About These Companies

Upstream Bio (NASDAQ:UPB) Trading 7.8% Higher - Should You Buy?

June 20, 2025 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Shares Gap Down - What's Next?

June 18, 2025 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Trading Down 3.4% - Here's What Happened

June 16, 2025 | marketbeat.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

June 15, 2025 | msn.com

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress

June 15, 2025 | quiverquant.comQ

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

June 15, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen

June 6, 2025 | marketbeat.com

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025

June 5, 2025 | quiverquant.comQ

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

June 5, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Trading Down 3.4% - Should You Sell?

June 4, 2025 | marketbeat.com

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Trading 10.2% Higher - Here's What Happened

June 3, 2025 | marketbeat.com

1,583,154 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Wellington Management Group LLP

June 1, 2025 | marketbeat.com

Jane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)

May 27, 2025 | marketbeat.com

Northern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)

May 27, 2025 | marketbeat.com

Upstream Bio names new chief technology officer

May 21, 2025 | investing.com

Upstream Bio Appoints Stacy Price As CTO

May 21, 2025 | nasdaq.com

Upstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical Operations

May 21, 2025 | nasdaq.com

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025 | globenewswire.com

Upstream Bio Advances Verekitug in Clinical Trials

May 7, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB, CGON, AVBP, JNJ, and UPB Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$22.81 +0.01 (+0.04%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$22.86 +0.05 (+0.22%)

As of 04:01 AM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

CG Oncology NASDAQ:CGON

$26.07 +0.01 (+0.04%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$26.16 +0.09 (+0.35%)

As of 04:00 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Johnson & Johnson NYSE:JNJ

$152.25 -0.03 (-0.02%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$152.29 +0.04 (+0.03%)

As of 04:42 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Upstream Bio NASDAQ:UPB

$10.94 +0.05 (+0.46%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$10.96 +0.02 (+0.14%)

As of 06/26/2025 04:04 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Upstream Bio NASDAQ:UPB

$10.94 +0.05 (+0.46%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$10.96 +0.02 (+0.14%)

As of 06/26/2025 04:04 PM Eastern

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time